First Solar, Green Mountain Coffee Roasters, Gilead Sciences, Idenix Pharmaceuticals, Transocean, LivePerson, Bristol-Myers Squibb and Banco Bilbao Vizcaya Argentaria SA are among the companies whose shares are moving in pre-market trading Thursday.

First Solar, Inc. (FSLR) stock rallied 23.58 percent to $18.29 in pre-market trading. The company reported the second quarter net income of $111.0 million or $1.27 per share, up from $61.1 million or $0.70 per share in the same period last year and also topped Reuters' estimate of $0.90 per share. First Solar also raised its fiscal 2012 adjusted earnings guidance to a range of $4.20 to $4.70 per share on revenues of $3.6 to $3.9 billion from its prior estimate of $4.00 to $4.50 per share on revenues of $3.5 to $3.8 billion.

Green Mountain Coffee Roasters Inc. (GMCR) stock climbed 12.78 percent to $20.20 in pre-market trading. Its third quarter adjusted net profit rose to $82.93 million or $0.52 per share from $75.75 million or $0.49 per share in the same period a last year and also topped analysts' estimate of $0.50 per share.

Gilead Sciences, Inc. (GILD) stock climbed 10.02 percent to $59.00 in pre-market trading. The stock has a 52-week low of $34.45, a 52-week high of $56.50 and $40.55 billion in market capitalization.

Idenix Pharmaceuticals, Inc. (IDIX) stock surged 8.17 percent to $9.00 in pre-market trading. The company stock slumped nearly 18 percent in regular trading Wednesday after announcing that it had commenced an underwritten registered public offering of $150 million of its common stock.

Transocean Ltd. (RIG) stock surged 4.10 percent to $49.76 in pre-market trading. The company swung to second quarter net loss of $304 million or $0.86 per share compared to net profit of $133 million or $0.39 per share in the same period a year-earlier. Revenue rose to $2.58 billion from $2.33 billion in the same period last year and also topped analysts' estimate of $2.49 billion.

LivePerson, Inc. (LPSN) stock tumbled 10.54 percent to $16.04 in pre-market trading. Its second quarter adjusted net profit declined to $2.86 million or $0.05 per share from $4.19 million or $0.08 per share in the same period last year. The company expects that the fiscal 2012 adjusted earnings will be in a range of $0.30 to $0.34 per share on revenues of $160 million to $165 million compared to analysts' estimate of $0.41 per share on revenues of $161.90 million.

Bristol-Myers Squibb Co. (BMY) stock plunged 3.09 percent to $34.50 in pre-market trading. The company announced Wednesday that it had suspended study drug administration in an ongoing Phase II study of BMS-986094, a nucleotide polymerase (NS5B) inhibitor in development for the treatment of hepatitis C.

Banco Bilbao Vizcaya Argentaria SA (BBVA) stock declined 2.67 percent to $6.55 in pre-market trading. The stock has a 52-week low of $5.30, a 52-week high of $9.96 and $36.22 billion in market capitalization.